Moderna mRNA vaccine with Merck ' s Keytruda cuts skin cancer recurrence by 44%
The risk of recurrence of deadly skin cancer reduced by 44% when patients were treated with a mRNA vaccine developed by Moderna and Merck& Co. ' s immunotherapy Keytruda drug, according to a new study.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Health | Immunotherapy | Merck | Skin | Skin Cancer | Study | Vaccines